An MD Anderson Cancer Center (MDACC) study, which collected 108 consecutive patients with t-MDS/t-AML showed that TP53 mutations in this setting were predominantly located in DNA-binding domains presenting an allelic frequency of 37% (range between 7.1 and 98.8). This evidence concerns the gene TP53 and acute myeloid leukemia.